NextFin News - GSK reported first-quarter core earnings that surpassed analyst expectations on Wednesday, as the British pharmaceutical giant successfully leveraged its high-margin HIV and oncology portfolios to offset a cooling market for its blockbuster respiratory syncytial virus (RSV) vaccine. The company posted core earnings of $1.13 per American depositary share, beating the Zacks Consensus Estimate of $1.08, even as total revenue of $9.46 billion (£7.52 billion) narrowly missed the $9.54 billion anticipated by the market.
The results highlight a strategic pivot under Chief Executive Officer Emma Walmsley, who has spent years narrowing the company’s focus toward specialty medicines. Sales in the Specialty Medicines division surged 17% at constant exchange rates, a performance that stood in stark contrast to the Vaccines franchise, which saw a 6% decline. This divergence underscores the volatility of the vaccine market, where the initial explosive demand for the Arexvy RSV shot has begun to normalize, leaving the company more dependent on its long-term chronic care treatments.
HIV treatments remained the bedrock of the quarter’s performance, with sales rising 7% as patients increasingly transitioned to newer, long-acting regimens. Dovato, a two-drug treatment, saw a 19% jump in revenue, while the long-acting injectable Apretude grew by 63%. These newer products are effectively cannibalizing GSK’s older three-drug regimens, such as Triumeq, which saw sales plunge 20%. This internal transition is critical for GSK as it seeks to protect its market share against competitors like Gilead Sciences before older patents expire later this decade.
Oncology also emerged as a significant growth engine, with sales of the endometrial cancer drug Jemperli continuing to gain traction. However, the broader market remains cautious about the sustainability of this growth. Some analysts, including those at Zacks Equity Research—who typically maintain a data-driven, neutral-to-positive outlook on large-cap pharma—noted that while the earnings beat is a positive signal, the revenue miss suggests that volume growth in certain segments may be hitting a ceiling. This perspective is not yet a consensus view, as many sell-side firms remain focused on the potential of GSK’s late-stage pipeline, including the recently approved asthma treatment depemokimab.
The company’s outlook for the remainder of 2026 remains tethered to its ability to maintain this momentum in specialty care while navigating a more difficult environment for its vaccine portfolio. While the earnings beat provides a temporary cushion, the slight revenue miss serves as a reminder of the pricing pressures and competitive dynamics in the primary care and vaccine markets. The success of the current strategy depends heavily on the continued adoption of long-acting HIV injectables and the successful commercial rollout of new oncology indications, both of which face rigorous competition and evolving regulatory landscapes.
Explore more exclusive insights at nextfin.ai.
